A
Anagenex
Biotech & Life Sciences · San Francisco, United States · Founded 2019
Biotechnology company building a novel platform for drug discovery focusing on difficult targets MoreLess
Anagenex is a biotechnology company focused on accelerating the drug discovery process by leveraging advanced machine learning and extensive biochemical datasets. Operating in the pharmaceutical and healthcare markets, Anagenex serves clients ranging from large pharmaceutical companies to research institutions. The company’s business model revolves around identifying and testing billions of custom synthesized compounds to find potential medicines that can modulate disease-causing proteins. By integrating expertise in biology, chemistry, and machine learning, Anagenex aims to reduce the time it takes to bring new medicines to market, thereby addressing unmet medical needs more efficiently. Revenue is generated through partnerships, licensing agreements, and potentially through the commercialization of discovered compounds.
Keywords: drug discovery, machine learning, biochemical datasets, pharmaceutical, healthcare, protein modulation, custom compounds, biology, chemistry, AI integration.
Company overview
Anagenex company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Francisco, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 61.5
Valuation & funding
Anagenex funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2022 | $30M | $120M | Obvious Ventures · Khosla Ventures · Lux Capital · Menlo Ventures | ↗ |
| SEEDEquity / VC | Jan 2022 | $7.2M | $29M | Menlo Ventures · Lux Capital · Obvious Ventures · Khosla Ventures | ↗ |
| SEED✓Equity / VC | Dec 2019 | — | — | Air Street Capital · Khosla Ventures | — |
| OtherOther financing | Jan 2019 | $0 | — | Undisclosed | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 5 |
| 2025 | 6 |
| 2024 | 27 |
| 2023 | 31 |
| 2022 | 22 |
| 2021 | 15 |
| 2020 | 7 |
Growth signals
Anagenex website traffic
Latest recorded traffic for Anagenex is 40K monthly website visits, up 11.1% over the last three months. Anagenex's team declined 16.7% over the past year.
Comparisons
Anagenex compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Anagenex's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Anagenex has talent and traffic
team presence
In the news
Latest news about Anagenex
Recent press, funding announcements, and product moves mentioning Anagenex — open to read from the original sources.
Market sentiment
What the market is saying about Anagenex
An AI-synthesized read of the highest-engagement posts about Anagenex on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anagenex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.